KYORIN Pharmaceutical (4569) Stock Overview
Through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
4569 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
KYORIN Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,150.00 |
| 52 Week High | JP¥1,725.00 |
| 52 Week Low | JP¥1,123.00 |
| Beta | -0.050 |
| 1 Month Change | -18.09% |
| 3 Month Change | -29.14% |
| 1 Year Change | -22.45% |
| 3 Year Change | -34.55% |
| 5 Year Change | -33.53% |
| Change since IPO | -22.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4569 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | -1.4% |
| 1Y | -22.5% | 7.2% | 41.1% |
Return vs Industry: 4569 underperformed the JP Pharmaceuticals industry which returned 7.2% over the past year.
Return vs Market: 4569 underperformed the JP Market which returned 41.1% over the past year.
Price Volatility
| 4569 volatility | |
|---|---|
| 4569 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.4% |
Stable Share Price: 4569 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4569's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 1,998 | Yutaka Ogihara | www.kyorin-pharm.co.jp |
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; and prescription medicines and quasi-drugs, and diagnostics business.
KYORIN Pharmaceutical Co., Ltd. Fundamentals Summary
| 4569 fundamental statistics | |
|---|---|
| Market cap | JP¥66.06b |
| Earnings (TTM) | JP¥3.45b |
| Revenue (TTM) | JP¥126.26b |
Is 4569 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4569 income statement (TTM) | |
|---|---|
| Revenue | JP¥126.26b |
| Cost of Revenue | JP¥74.63b |
| Gross Profit | JP¥51.62b |
| Other Expenses | JP¥48.18b |
| Earnings | JP¥3.45b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 60.02 |
| Gross Margin | 40.89% |
| Net Profit Margin | 2.73% |
| Debt/Equity Ratio | 16.4% |
How did 4569 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/13 00:09 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KYORIN Pharmaceutical Co., Ltd. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |